A Global Study of Volrustomig (MEDI5752) Plus Chemotherapy Versus Pembrolizumab Plus Chemotherapy for Participants With Metastatic Non-small Cell Lung
A phase 3 trial of Pembrolizumab, Carboplatin, Paclitaxel / nab-paclitaxel in non-small-cell lung cancer and small-cell lung cancer, run by AstraZeneca, active and no longer recruiting.
Overview
A Global Study of Volrustomig (MEDI5752) Plus Chemotherapy Versus Pembrolizumab Plus Chemotherapy for Participants With Metastatic Non-small Cell Lung Cancer. is a phase 3 interventional study registered as NCT05984277 by AstraZeneca, with 895 participants enrolled, started 2023-10-24 and due to reach its primary completion in 2029-02-28. Interventions recorded: Volrustomig, Pembrolizumab, Carboplatin, Paclitaxel, Pemetrexed. Conditions listed: Metastatic Non-small Cell Lung Cancer. No results are recorded here; the registry entry is the source.
Similar pages
not linked directly; found by shared links- TrialVolrustomig Priming Regimens Exploratory Phase II Platform Study
Shares Pemetrexed, Paclitaxel / nab-paclitaxel, AstraZeneca, Carboplatin.
- TrialA Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Squamous Non-s
Shares Paclitaxel / nab-paclitaxel, AstraZeneca, Carboplatin, Pembrolizumab.
- TrialStudy of Pembrolizumab (MK-3475) Subcutaneous (SC) Versus Pembrolizumab Intravenous (IV) Administered With Platinum Doublet Chemotherapy in Participan
Shares Pemetrexed, Paclitaxel / nab-paclitaxel, Carboplatin, Pembrolizumab.
- TrialA Study to Investigate the Efficacy and Safety of Trastuzumab Deruxtecan as the First Treatment Option for Unresectable, Locally Advanced/Metastatic N
Shares Pemetrexed, AstraZeneca, Carboplatin, Pembrolizumab.
- TrialIPH5201 and Durvalumab in Patients With Resectable Non-Small Cell Lung Cancer (MATISSE)
Shares Pemetrexed, Paclitaxel / nab-paclitaxel, Carboplatin, Small-cell lung cancer.
- TrialA Study of Pembrolizumab With or Without Chemotherapy in Combination With Additional Treatments for Advanced Non-Small Cell Lung Cancer (NSCLC) (MK-34
Shares Pemetrexed, Paclitaxel / nab-paclitaxel, Carboplatin, Pembrolizumab.
- TrialA Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Non-Squamous N
Shares Pemetrexed, AstraZeneca, Carboplatin, Pembrolizumab.
- TrialSafety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung Cancer
Shares Pemetrexed, Paclitaxel / nab-paclitaxel, Carboplatin, Pembrolizumab.